Insulet Corporation is set to host its Investor Day on June 5, 2025, which will discuss the future of its tubeless insulin pump technology. In recent years, the company's shareholders have observed lagging YoY returns, despite a 15% five-year earnings growth. RBC Capital has initiated coverage of Insulet with an outperform recommendation. Insulet's shares, however, saw a 12% decline after revealing a net income decrease. Despite this, the company’s sales keep rising, with the Q4 2024 earnings call indicating record revenue and strategic expansion. Insulet’s Q4 beat revenue expectations and saw slightly exceeded quarterly revenue guidance. Moreover, Insulet launched its Omnipod® 5 in five additional European countries, expanded the groundbreaking device to five new European markets, and added dual CGM support. The Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes. Also, the PODD stock is gaining from the launch of Omnipod 5 in five EU countries and with Abbott's CGM in the US. A highlight for the company was its massive $452M victory in a medical device legal battle, successfully defending its intellectual property against EOFlow Co. in U.S. District Court.
Insulet Corporation PODD News Analytics from Tue, 14 May 2024 07:00:00 GMT to Fri, 14 Mar 2025 22:30:19 GMT - Rating 7 - Innovation 4 - Information 8 - Rumor 5
